US › Healthcare

INmune Bio Inc (INMB)

US · Healthcare · Biotechnology

$1.13-3.83%

Last close · 2026-11-06

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-1.3M

EPS

$-0.05

EPS estimate

$-0.20

EPS came in at -0.05 against a street estimate of -0.20 — a beat of 75.0%.

Key statistics

Market cap

$36.4M

Forward P/E

0.0

P/B

1.99

Book value

$0.74

EPS (TTM)

$-0.60

52-week high

$2.60

52-week low

$1.06

50-day MA

$1.93

200-day MA

$1.63

Beta

0.94

Analyst view

Analysts rate INmune Bio Inc a strong buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $7.00.

Shareholding

Insiders

10.75%

Institutions

15.59%

Largest institutional holders

Fund	Stake
Vanguard Capital Management, LLC	2.55%
AQR Capital Management LLC	2.39%
BlackRock Inc	1.12%
Geode Capital Management, LLC	0.69%
The Goldman Sachs Group Inc	0.67%
Millennium Management LLC	0.57%
Susquehanna International Group, LLP	0.57%
Jane Street Group LLC	0.48%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for INmune Bio Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-11-07.